Leveraging PD-L1 Inhibitors for Metastatic Esophageal Squamous Cell Carcinoma

Meeting Objectives:

• • Identify unmet needs for patients with metastatic esophageal SCC and recent trends in using PD-L1 in this treatment space.
  • Analyze the latest updates in therapy guidelines and emerging treatment data from clinical trials related to PD-L1 therapy in metastatic esophageal SCC, in order to make informed, patient-specific recommendations through interactive review of complex patient cases.
  • Discuss the integral role of pharmacists in the management of metastatic esophageal SCC with PD-L1 therapy, including formulary management, optimizing patient selection, education, and monitoring.